Eli Lilly initiates first international, observational study to understand barriers to progression of insulin treatment

US drug major Eli Lilly (NYSE: LLY) says it is conducting the first major international, prospective observational study designed to understand the real-world obstacles that people with type 2 diabetes face that prevent them from reaching their ultimate treatment goals.

Many people with diabetes who take daily insulin resist a progression of insulin therapy that could help them reach their ideal blood sugar target. The MOSA1c (A Multinational Observational Study Assessing Insulin use: Understanding the challenges associated with the progression of therapy) study will seek to determine why that is by gathering data on insulin use, interactions between people with and treating diabetes and other factors involved in the progression of treatments used to manage diabetes.

Despite treatment, many people with type 2 diabetes do not reach blood glucose (HbA1c) goals after initiation of insulin therapy, exposing them to an increased risk of serious complications. These results are consistent across studies and geographies.